10 Best 52-Week Low NASDAQ Stocks to Buy According to Billionaires

Page 1 of 3

Scan the Nasdaq stocks hitting 52-week lows this week and a pattern jumps out: many of the biggest names build, power or rent space for artificial intelligence. Few of these businesses are shrinking. Several reported record revenue in recent weeks, and their shares kept sliding anyway.

The reason has less to do with earnings than with money and politics, and both turned sharply worse over the past month.

Credit Fears Hit the AI Builders First

The first shock came from the bond market. CoreWeave has taken on more than $51 billion of debt and obligations to build its AI infrastructure, CNBC reported on October 15. By October 21, CNBC said, its shares were down 36% for the month, and the spread on its five-year credit default swaps, a measure of the cost of insuring its debt, had reached 1,145 basis points. Barclays credit analyst Andrew Keches told clients that sentiment toward AI bonds was “decidedly negative.”

Readers weighing the pullback can read our analysis of whether CoreWeave’s recent drop is a buying opportunity.

More pressure followed. Elon Musk said more than 200 neoclouds, the companies that rent out AI computing power, would see “guppy-level death and consolidation,” CNBC reported on October 26. Two days later, Microsoft reported capital spending below analyst estimates and said some third-party capacity it expected had been delayed, CNBC reported on October 28. Neocloud stocks fell again.

A New Political Risk Arrives in Washington

Then came the election. Reuters reported on November 4 that Wall Street closed sharply higher after Democrats won Congress, but data center shares fell on fears of tighter AI regulation. Democrats made gains in Texas and Georgia, where public opposition to the industry’s rapid expansion has been growing.

The market split in two. Shares of cash-rich AI heavyweights rose, while chipmakers and data center operators fell: Hut 8 lost 23%, IREN 11%, Core Scientific 10% and Applied Digital 6.7%. Citi Research’s head of US equity strategy, Scott Chronert, said any change in the pace of the buildout alters the outlook for many of those suppliers.

We also wrote about how leverage turned an AI bet into a fire sale for one fund.

The pressure carried into the next day. UBS analysts estimated that around 30% of expected US data center capacity additions in 2028 could be at risk from potential construction pauses, Reuters reported on November 5. Large technology companies, by contrast, rose on the view that a slower buildout would curb their own spending, Reuters said.

Our Methodology

For this article, we used Finviz to screen for NASDAQ-listed stocks that hit a new 52-week low as of November 5, 2026. We then checked how many of the 107 billionaires we track held each stock as of Q2 2026, and ranked the 10 with the most billionaire holders in ascending order. We also list each stock’s number of hedge fund holders as of Q2 2026, from our database of 1,006 hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10 Best 52-Week Low NASDAQ Stocks to Buy According to Billionaires

10. IREN (NASDAQ:IREN)

Number of Billionaire Holders: 16

Number of Hedge Fund Holders: 69

The sell-off in IREN began with a forecast, not a failure. Gartner predicted that 80% of neocloud companies will be absorbed or stop operating by 2030, CNBC reported, and Elon Musk soon warned that more than 200 of them face consolidation. IREN had already dropped 40% in a month by then. Reuters said the shares fell another 11% after the midterm elections raised fears of tighter oversight of data centers.

Bulls say the contracts tell a different story. The company is turning bitcoin-mining sites into AI data centers, and it signed a $9.7 billion deal with Microsoft. In its latest annual results, it reported $4 billion of annualized revenue contracted for 2026 capacity and said that capacity was largely sold out. Customers have also been prepaying, covering 45% to 55% of the cost of new chips, which eases some of the borrowing worry hanging over the group. If customers keep prepaying and the capacity stays sold out, bulls argue the company can fund growth without leaning as hard on lenders, which is the very worry weighing on neocloud shares.

We covered how IREN swapped bitcoin rigs for Microsoft GPU contracts if you want the backstory.

9. NewAmsterdam Pharma (NASDAQ:NAMS)

Number of Billionaire Holders: 18

Number of Hedge Fund Holders: 45

NewAmsterdam Pharma sank to a new low late last month even after winning the first approval of its cholesterol drug anywhere. The company has no drug sales yet, so its value rides on one question: whether obicetrapib, a once-daily pill that lowers LDL cholesterol, cuts heart attacks and strokes. That answer comes from PREVAIL, a trial that randomized more than 9,500 patients. An interim analysis is planned for this quarter, with a result expected in early 2027, and investors are waiting.

Bulls like how much has already gone right. The European Commission approved obicetrapib alone and combined with ezetimibe, the first approval worldwide, and its partner Menarini helped lift third-quarter revenue to $19.2 million through regulatory milestones. NewAmsterdam ended September with $643.1 million in cash and has started a new study in preclinical Alzheimer’s disease. That cash gives it room to wait for the trial data. A positive PREVAIL result would give the pill a stronger case with patients whose cholesterol stays high despite treatment.

Our earlier coverage of how EU approvals could turn into royalties for NewAmsterdam looks at the revenue side.

Page 1 of 3